Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-MR D2 Receptor Imaging in Nonfunctioning Pituitary Adenoma
NCT03714763Unknown
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands
01
Overview
Open-label trial of cabergoline and bromocriptine (2 arms). Primary endpoint: Change from baseline on tumor volume at 6 months. Status: unknown.
02
Drugs
cabergolinebromocriptine
Beyond the preview
Go deeper on NCT03714763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714763.